Gaithersburg, MD, 29 September 2016 – MaxCyte®, Inc., an established and revenue generating US-based developer and supplier of cell engineering products and services to biopharmaceutical firms engaged in cell therapy, drug discovery and development, biomanufacturing, gene editing and immuno-oncology, announced today company leadership will be presenting at and participating in two industry conferences next week. Details follow:
2016 Cell & Gene Meeting on the Mesa
MaxCyte’s Jessica Carmen, Ph.D., Director of Business Development, Cellular Therapies, will be joining a panel for the Gene Therapy Manufacturing Workshop, entitled “Strategies for BioManufacturing Viral-based Gene Therapy Vectors – Early-Stage Development Through Clinical Production.”
October 5, 2016 at 7:15a.m.
Estancia La Jolla Hotel & Spa
MaxCyte’s Madhusudan Peshwa, Ph.D., Chief Scientific Officer, and EVP, Cellular Therapies, will be presenting during the Partnering Forum.
October 5, 2016 at 1:15 p.m.
Estancia La Jolla Hotel & Spa
Note: A live video webcast of all company presentations will be available at: //www.meetingonthemesa.com/webcast/ and will also be published on the Alliance for Regenerative Medicine’s website shortly after the event.
Biotech Week Boston 2016 – BioProcess International Conference & Exposition
MaxCyte’s Joan Hilly Foster, Senior Field Applications Scientist, will be presenting
“Accelerating Biotherapeutic Development Using Scalable CHO Cell Transfection.”
October 5, 2016 at 12:05 p.m.
Boston Convention & Exhibition Center
Find complete details for this presentation here: //bit.ly/2dhHdyN
Two scientific posters will also be presented:
– “Streamlining Production of Biologics, Vaccines & Cell-based Medicines using a Single Fully Scalable Transfection Platform”
– “Consistent Antibody Quality and Glycosylation Patterns Support the Use of MaxCyte’s Electroporation-based Transfection for Biotherapeutic Product Development”
Stop by Booth #1045 during the BioProcess International Convention & Exposition, October 5-7, 2016 to learn more about MaxCyte.
# # #
MaxCyte is an established and revenue generating US-based developer and supplier of cell engineering products and services to biopharmaceutical firms engaged in cell therapy, drug discovery and development, biomanufacturing, gene editing and immuno-oncology markets, which independent market analyses estimate to be, in aggregate, in excess of $35 billion in 2015. The Company’s patented flow electroporation technology enables its products to deliver fast, reliable and scalable cell engineering to drive the research and clinical development of a new generation of medicines.
MaxCyte’s high performance platform allows transfection with any molecule or multiple molecules and is compatible with nearly all cell types, including hard-to-transfect human primary cells. It also provides a high degree of consistency and minimal cell disturbance, thereby facilitating rapid, large scale, clinical and commercial grade cell engineering in a non-viral system and with low toxicity concerns. The Company’s cell engineering technology platform is CE-marked and FDA-accredited, providing MaxCyte’s customers and partners with an established regulatory path.
Using the unique capabilities of its technology, MaxCyte is developing CARMA, its proprietary platform in immuno-oncology, to deliver a validated non-viral approach to CAR therapies across a broad range of cancer indications, including solid tumors where existing CAR-T approaches face significant challenges.
For more information visit /
|MaxCyte||+1 301 944 1660|
|Doug Doerfler, Chief Executive OfficerMarkus Hunkeler, Vice President, Marketing|